Fascin-1 is associated with recurrence in solitary fibrous tumor/hemangiopericytoma

YUMIKO YAMAMOTO1, YOSHIHIRO HAYASHI2, HIDEYUKI SAKAKI3 and ICHIRO MURAKAMI1,4

1Department of Diagnostic Pathology, Kochi University Hospital, Kochi University; 2Equipment of Support Planning Office, Kochi University, Nankoku, Kochi 783-8505; 3Department of Nutritional Sciences for Well-being Health, Kansai University of Welfare Sciences, Kashiwa, Osaka 582-0026; 4Department of Pathology, School of Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan

Received March 31, 2021; Accepted July 15, 2021

DOI: 10.3892/mco.2021.2361

Abstract. Fascin-1, an actin-bundling protein, is associated with poor prognosis in patients with various types of human carcinoma. However, research is limited on the role of fascin-1 in sarcoma. Solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) are rare sarcomas derived from the mesenchyme. Although the prognosis of SFT/HPC is generally favorable, fatalities are possible with repeated recurrence and distant metastasis. The current study included a total of 20 Japanese patients, who were diagnosed with SFT/HPC and underwent surgery at Kochi University Hospital from January 2000 to December 2019. The statistical relationship between recurrence and the following variables were examined: Sex, age of onset, tumor origin, tumor size, necrosis, mitosis ≥1/10 high power field (HPF; magnification, x400), Ki-67 >5% and Fascin-1. A significant association was determined between recurrence and necrosis, mitosis ≥1/10 HPF (magnification, x400), Ki-67 >5%, and Fascin-1 ≥strongly positive’ (P<0.05). The results demonstrated that Fascin-1 immunostaining may be a highly effective and useful evaluation factor for predicting poor prognosis in patients with SFT/HPC, a fatal sarcoma of humans.

Introduction

Solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) are rare tumors derived from mesenchyme. SFT and HPC were formerly considered to be different diseases, however closely related due to similarities observed in immunohistochemical positive staining in CD34, CD99, vimentin, BCL2, and epithelial membrane antigen (1-5). This lack of specificity in SFT/HPC occasionally caused problems in differentiating them from other tumors that are immunohistologically alike. In 2013, three groups reported that SFT and HPC have a common gene fusion between NGFI-A-binding protein 2 (NAB2) and signal transducer and activator of transcription 6 (STAT6) (1.6,7). Thereafter, STAT6, which has dual functions as a signal transducer and as transcription activator in SFT and HPC, was recognized as the highly sensitive and specific immunohistochemical marker for SFT/HPC (2-5,8-11).

Clinical progression of SFT/HPC is different in each case. For example, we reported one case where it was diagnosed accidentally and treated completely by a successful surgery, whereas in other cases relapse occurred with local recurrence and/or multiple metastases after many years of surgical treatment followed by radiotherapy and/or intensive chemotherapy (1,3,9,10,12-18). Regardless of the many attempts that have been made to classify NAB2-STAT6 fusion variants to prognose clinical characteristics of SFT/HPC, absolute fusion variant related to malignancy has not yet been detected (11,19,20). However, recently classical grading of SFT/HPC with histopathological backgrounds, such as mitosis and necrosis, have been reevaluated to detect factors that may be associated with a malignant prognosis (15,16,21). Furthermore, several groups reported that Ki-67, a protein widely known to associate with a poor prognosis in various cancers (2,22-25), is related to recurrence in SFT/HPC derived from the pleura and central nervous system (2,14,15). We also detected a significant relationship to recurrence between necrosis, mitosis ≥1/10 HPF (magnification, x400), and Ki-67 >5% in SFT/HPC regardless of its origin (26).

In this study, we added evaluation of Fascin-1 immunostaining as a potential factor that may predict recurrence of SFT/HPC. Fascin-1, an actin-bundling protein, plays an important role in the regulation of cell adhesion, migration and invasion (27,28). It is known that Fascin-1 has a strong upregulation in various human carcinomas. However, regarding sarcomas, there are only a few earlier reports (29). Our study showed that Fascin-1 was strongly associated with recurrence of SFT/SFT and it suggested that Fascin-1 could be used as a predictive factor for malignancy of SFT/HPC.
| Case | Sex | Age of onset (years) | Tumor location            | Tumor size (cm) | STAT6 | Ki-67 >5% | Mitosis ≥1/10 HPF | Necrosis | Fascin-1 | Recurrence free months |
|------|-----|---------------------|---------------------------|-----------------|-------|----------|-------------------|----------|----------|------------------------|
| I    | F   | 80-89               | Bone and soft tissue      | 3.5             | +     | -        | -                 | -        | +        | -                       |
| II   | F   | 50-59               | Bone and soft tissue      | 10.5            | +     | -        | -                 | -        | -        | -                       |
| III  | M   | 50-59               | Bone and soft tissue      | 12.5            | +     | -        | -                 | -        | -        | -                       |
| IV   | M   | 70-79               | Bone and soft tissue      | 10.0            | +     | -        | -                 | -        | -        | -                       |
| V    | M   | 60-69               | Bone and soft tissue      | 15.0            | +     | -        | -                 | -        | +        | -                       |
| VI   | M   | 30-39               | Bone and soft tissue      | 11.0            | +     | -        | -                 | -        | -        | -                       |
| VII  | F   | 70-79               | Bone and soft tissue      | 10.0            | +     | -        | -                 | -        | -        | -                       |
| VIII | F   | 50-59               | Bone and soft tissue      | 12.5            | +     | -        | -                 | -        | -        | -                       |
| IX   | F   | 60-69               | Bone and soft tissue      | 9.0             | +     | -        | -                 | -        | -        | -                       |
| X    | F   | 50-59               | Head and neck             | 1.7             | +     | +        | -                 | -        | +        | -                       |
| XI   | F   | 60-69               | Lung                      | 4.0             | +     | -        | -                 | -        | -        | -                       |
| XII  | M   | 70-79               | Lung                      | 6.0             | +     | +        | +                 | -        | +        | -                       |
| XIII | M   | 30-39               | Lung                      | 14.0            | +     | -        | -                 | -        | +        | -                       |
| XIV  | F   | 50-59               | Lung                      | 8.0             | +     | -        | -                 | -        | -        | -                       |
| XV   | F   | 30-39               | CNS                       | 1.0             | +     | -        | +                 | -        | Strongly positive +     | 136        |
| XVI  | M   | 60-69               | CNS                       | 5.0             | +     | -        | -                 | -        | -        | -                       |
| XVII | F   | 50-59               | CNS                       | 2.0             | +     | -        | -                 | -        | -        | -                       |
| XVIII| F   | 60-69               | CNS                       | 1.0             | +     | +        | +                 | -        | +        | -                       |
| XIX  | F   | 30-39               | CNS                       | 5.5             | +     | +        | +                 | -        | Strongly positive +     | 49         |
| XX   | F   | 60-69               | CNS                       | 1.5             | +     | -        | +                 | -        | -        | -                       |

STAT6, signal transducer and activator of transcription 6; F, female; M, male; CNS, central nervous system; +, positive; -, negative; HPF, high power field (magnification, x400).
Materials and methods

Materials. A total of 20 Japanese patients, previously diagnosed with SFT/HPC at Kochi University Hospital from January 2000 to December 2019, were included in this study. Table I shows the backgrounds of these patients. All patients underwent one or more tumor resection surgery. Tissues obtained during surgery were embedded in paraffin blocks after formalin fixation and preserved. All patients were observed at Kochi University Hospital following surgery. Seven cases had one or more recurrence and two patients (cases III and VII) died due to the disease.

Immunohistochemical examination and evaluation. For the present study, formalin-fixed paraffin-embedded tissue samples were freshly cut into 4 µm thick slices and heat-treated with ULTRA cell conditioning 1 retrieval solution (CC1; Ventana Automated Systems). Immunohistochemical examination was performed using a Ventana automated system with the following antibodies: STAT6 (D‑1, sc‑374021, dilution 1:50; Santa Cruz Biotechnology, Inc.), Ki‑67 (MIB‑1, dilution 1:50; Dako; Agilent Technologies, Inc.), and anti‑Fascin‑1 mouse monoclonal antibody (55k‑2, dilution 1:50; Dako; Agilent Technologies, Inc.). Immunohistochemical expression of STAT6, Ki‑67, and Fascin‑1 was evaluated in the density of the nuclear staining and graded as ‘negative’, ‘weak’, ‘moderate’, or ‘strong’. Grades ‘moderate’ and ‘strong’ were then defined as ‘positive’ in terms of diagnosis. To investigate the proportion of positive Ki‑67, a total of 100 tumor cells were counted at five different hot spots. Then, the mean value of positive cells was calculated and input as a percentage for statistical analysis. As for the evaluation for Fascin‑1, the intensity and extent of staining were examined (28,29). The intensity of staining was scored as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The extent of staining was scored as 0 (0%), 1 (1‑20%), 2 (21‑70%), and 3 (71‑100%). When the sum of staining intensity and extent scores was 2-4 and 5-6, it was defined as ‘positive’ and ‘strongly positive’, respectively. Independent evaluation of immunostaining was performed by two different expert pathologists who were blinded to the clinical data.

Statistical analysis. Statistical relationship was examined between recurrence and the following variables: Sex, onset age, tumor origin, tumor size, mitosis ≥1/10 HPF (magnification, x400), necrosis, Ki‑67>5% and Fascin‑1. Pearson’s correlation coefficient analysis was applied to detect relationship between recurrence and sex, tumor origin, necrosis, mitosis ≥1‑10 HPF (magnification, x400), or Ki‑67>5%. Logistic regression analysis was applied to compare recurrence with tumor size. Wilcoxon rank test was applied to compare recurrence with onset age and Fascin‑1 ≥‘strongly positive’.

Results

Clinical background of patients. Table I includes the results of histopathological and immunohistochemical evaluation of all cases.

Fascin‑1 staining. Table II shows sensitivity, false positive rate, and concordance rate in two proposed groups with different cut-off points of Fascin‑1 immunostaining. When the cut-off point for Fascin‑1 staining for the judgement of recurrence (+) was between ‘positive’ and ‘strongly positive’, where sensitivity, false positive rate and concordance were 0.71, 0.00 and 0.90, respectively.
point was set between ‘positive’ and ‘strongly positive’, the sensitivity, false positive rate, and concordance were 0.71, 0.00, and 0.90, respectively. On the other hand, when the cut-off point was set between ‘negative’ and ‘positive’, its sensitivity, false positive rate and concordance were 0.71, 0.46 and 0.6, respectively. By these findings, the most effective cut-off point of Fascin‑1 was determined to be between ‘positive’ and ‘strongly positive’.

Statistical analyses. Table III shows the results of relationship between recurrence and each variable. A significant relationship to reference was detected with necrosis (P<0.05), mitosis ≥1/10 HPF (magnification, x400) (P<0.01), Ki‑67 >5% (P<0.01), and Fascin‑1 ≥‘strongly positive’ (P<0.01). Sex, onset age, tumor size, or tumor origin did not relate to recurrence. Fig. 1 shows representative images of the microscopic and immunohistochemical findings, specifically from Case XVI and Case XIX, where Fascin‑1 was ‘negative’ in Case XVI and was ‘strongly positive’ in Case XIX. Fig. 2 shows Kaplan‑Meier curve of patients with Fascin‑1 ‘strongly positive’ or not.

Discussion

SFT and HPC had long been regarded as different tumors since 1931, when Klemperer and Coleman first reported on primary mesenchymal tumors of the pleura (29). However, after the year 2000, controversial discussions about the classification of SFT/HPC prompted a unification of these tumors into a single disease entity. As a result, the 2013 WHO Classification of Tumors of Soft Tissue and Bone removed the term ‘hemangiopericytoma’ as a synonym for SFT, joining these tumors together as SFT under the category of fibroblastic/myofibroblastic tumors (5,8,30‑32). In the same year, the common gene fusion between NAB2 and STAT6 was discovered in SFT/HPC. The 2016 WHO Classification of Tumors of the Central Nervous System designated these tumors, characterized by the NAB2‑STAT6 gene fusion, as SFT/HPC in mesenchymal/non‑mesenchymal tumors (2,9,33,34).

The discovery of the NAB2‑STAT6 gene fusion, has resulted in both quicker and more accurate diagnosis of SFT/HPC. Cases difficult to diagnose with classical immunostainings, such as CD34, CD99, and vimentin, can easily be definitively diagnosed as SFT/HPC through the evaluation of STAT6 immunostaining. The prognosis of SFT/HPC is generally favorable, however, fatalities are possible with repeated recurrence and distant metastasis. In this study, seven of 20 cases had recurrence and two patients passed away due to the disease. The advancement of diagnostic techniques for SFT/HPC by STAT6 immunostaining may result in more cases being properly diagnosed in the future. Therefore, it is crucial for clinicians to identify patients with high risk of recurrence to adequately carry out their follow‑ups.

Previously, we reported that recurrence of SFT/HPC was significantly related to necrosis, mitosis ≥1/10 HPF (magnification, x400), and Ki‑67 >5% (26). Here, an
additional factor potentially related to recurrence has been added, specifically, Fascin-1 immunostaining. Fascin-1, an actin-bundling protein, plays an important role in the regulation of cell adhesion, migration, and invasion (27-29,35). Fascin-1 widely exists in different tissues of the human body, such as mesenchyme and nervous tissue, however it is not present in most normal epithelia. Fascin-1 has been commonly observed to be highly upregulated in various human carcinomas (27,28). Furthermore, the overexpression of Fascin-1 is positively correlated with poor prognosis of carcinomas, because it increases the chance of metastasis. Regarding sarcomas, few reports had been made about any relationship with Fascin-1. However, after 2019, Arlt et al reported Fascin-1 expression also correlates with progression and metastasis in osteosarcoma and chondrosarcoma (29). Additionally, Richmond et al reported that Fascin-1 is a mediator of invasion in uterine carcinosarcoma as a component of epithelial-mesenchymal transition (35).

Since 2012, pazopanib hydrochloride, a broad-spectrum tyrosine kinase inhibitor, has been approved for the treatment of soft tissue sarcoma in Japan, and its effectiveness has been reported in several papers (36,37). In this study, three patients (Case VII, XV and XI) had been treated with pazopanib hydrochloride, however, Case VII patient passed away within six months following its administration. The development of new medicines that may directly target the NAB2-STAT6 gene fusion is desired for patients with SFT/HPC. Furthermore, additional therapeutics that may target and inhibit Fascin-1 will also greatly benefit patients with malignant tumors.

We attempted to detect the relationship between Fascin-1 immunostaining and recurrence of SFT/HPC. Presently, classical histological findings, such as mitosis and necrosis, are generally accepted to be useful to prognose its recurrence. As shown in Table I, sensitivity of mitosis was excellent, but there was a false-positive case. As for necrosis, its specificity was excellent, but there were four false-negative cases, which implied necrosis was not a clinically favorable factor to predict its recurrence. Regarding Fascin-1, as shown in Tables I and II, sensitivity was 0.71 and two cases had false-negative, although, its false-positive rate was 0.0 and it was negative in Case XX, where mitosis had a false-positive. By using two factors, Fascin-1 and mitosis, recurrence in SFT/HPC could be prognosed more accurately. To confirm the benefit of Fascin-1 as a factor to predict recurrence in SFT/HPC, further studies with more cases should be performed in the future. However, in this study, we observed Fascin-1 immunostaining to be one of the most effective and useful evaluation factors to predict poor prognosis in patients with SFT/HPC. Through a meticulous histological and immunochemical observation of these factors after the initial surgery, clinicians should be better informed during follow-ups with patients most at risk for recurrence and subsequently able to treat them at early stages of recurrence.

The evaluation of Fascin-1 immunostaining is useful for recurrence prediction of SFT/HPC. These data indicate that Fascin-1 may play an important role in the recurrence of SFT/HPC, one of sarcomas.

Acknowledgments

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

YY and YH conceived the current study. YY and YH performed the histological examination. YY and HS performed statistical analysis. YY and IM made substantial contributions to study conception and design. IM critically revised the manuscript and gave final approval for the manuscript to be published. All authors read and approved the final manuscript. YY and YH confirmed the authenticity of all the raw data.

Ethics approval and consent to participate

The current study was reviewed and approved by the Ethics Committee for Clinical Research of the School of Medicine, Kochi University (approval no. ERB-105384). All procedures were carried out with adequate understanding and the written consent of each patient.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, Chen CL, Zhang L, Wang R, Su F, et al: Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumors by integrative sequencing. Nat Genet 45: 180-185, 2013.
2. Shukla P, Gulwani HV, Kaur S and Shanmugasundaram D: Reappraisal of morphological and immunohistochemical spectrum of intracranial and spinal solitary fibrous tumors/hemangioendotheliomas with impact on long-term follow-up. Indian J Cancer 55: 214-221, 2018.
3. Davanzo B, Emerson RE, Lisy M, Koniaris LG and Kays JK: Solitary fibrous tumor. Transl Gastroenterol Hepatol 3: 94, 2018.
4. Zhang Q, Qin J, Li Y and Wu T: Primary solitary fibrous tumor of kidney: A case report and literature review. Urol Case Rep 23: 92-94, 2019.
5. Doyle LA, Vivero M, Fletcher CD, Mertens F and Hornick JL: Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol 27: 390-395, 2014.
6. Chmielecki J, Crago AM, Rosenberg M, O'Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA and Meyerson M: Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45: 131-132, 2013.
7. Mohajeri A, Tayebwa J, Collin A, Nilsson J, Magnusson L, von Steyern FV, Brosjö O, Domanski HA, Larsson O, Sciot R, et al: Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer 52: 873-886, 2013.
8. Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, Pusch S, Habel A, Meyer J, Giék T, et al: Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125: 651-658, 2013.

9. Rinaldo L, Xu SCY, Eggers SD, Salomão DR, Chen JJ and Raghunathan A: Rare occurrence of an intracranial choroidal solitary fibrous tumor/hemangiopericytoma. Ocul Oncol Pathol 4: 213-219, 2018.

10. Tai HC, Chuang IC, Chen TC, Li CF, Huang SC, Kao YC, Lin PC, Tsai JW, Lan J, Yu SC, et al: NAB2-STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors. Mod Pathol 28: 1324-1335, 2015.

11. Kakkar A, Sakthivel P, Rajeshwari M, Kairo A and Sharma MC: Recurrent sinonasal CD34-negative malignant solitary fibrous tumor diagnosed on STAT6 immunohistochemistry and NAB2-STAT6 fusion. Head Neck Pathol 14: 250-256, 2020.

12. Penel N, Amelia EY, Decanter G, Robin YM and Marec-Berard P: Solitary fibrous tumors and so-called hemangiopericytoma. Sarcoma 2012: 69251, 2012.

13. Thway K, Ng W, Noujaim J, Jones RL and Fisher C: The current status of solitary fibrous tumor: Diagnostic features, variants, and genetics. Int J Surg Pathol 24: 281-292, 2016.

14. Schmid C, Csanan D, Kaifi JT, Küler M, Haager B, Kayser G, Passlick B and Wiesemann S: Prognostic factors in solitary fibrous tumors of the pleura. J Surg Res 195: 580-587, 2015.

15. Diebold M, Soltermann A, Hottinger S, Halie SR, Bubendorf L, Komminoth P, Jochum W, Grobholz R, Theegarten D, Berezowska S, Komminoth P, Kusters B, Wesseling P, Figarella-Branger D, et al: Prognostic significance of NAB2-STAT6 fusion variants and TERT promoter mutations in solitary fibrous tumors/hemangiopericytomas. Acta Neuropathol 137: 371-383, 2019.

16. Fountas KN, Kapsalaki E, Kassam M, Feltes CH, Dimopoulos VG, Robinson JS and Smith JR: Management of intracranial meningeal hemangiopericytomas: Outcome and experience. Neurosurg Rev 29: 145-153, 2006.

17. Robinson LA: Solitary fibrous tumor of the pleura. Cancer Control 13: 264-269, 2006.

18. Ghose A, Guha G, Kundu R, Tew J and Chaudhary R: CNS hemangiopericytoma: A systematic review of 523 patients. Am J Clin Oncol 40: 223-227, 2017.

19. Yuzawa S, Nishihara H, Wang L, Tsuda M, Kimura I, Tanino M and Tanaka S: Analysis of NAB2-STAT6 gene fusion in 17 cases of meningeal solitary fibrous tumor/hemangiopericytoma: Review of the literature. Am J Surg Pathol 40: 1031-1040, 2016.

20. Vogels R, Macagno N, Griewank K, Groeneweg P, Verdijk M, Fonville J, Küsters B; French CNS SFT/HPC Consortium; Dutch CNS SFT/HPC Consortium, Figarella-Branger D, et al: Prognostic significance of NAB2-STAT6 fusion variants and TERT promoter mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: Not (yet) clear. Acta Neuropathol 137: 679-682, 2019.

21. England DM, Hochholzer L and McCarthy MJ: Localized benign pericytomas of the CNS: Not (yet) clear. Acta Neuropathol 137: 679-682, 2019.

22. Arlt MJ, Kuzmanov A, Snedeker JG, Fuchs B, Silvan U and Sabile AA: Fascin-1 enhances experimental osteosarcoma tumor formation and metastasis and is related to poor patient outcome. BMC Cancer 19: 85, 2019.

23. Barthelmes S, Geddert H, Boltze C, Moskalev EA, Bieg M, Sirbu H, Brors B, Wiemann S, Hartmann A, Agaimy A and Haller F: Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am J Pathol 184: 1209-1218, 2014.

24. Doyle LA: Sarcoma classification: An update based on the 2013 World Health Organization classification of tumors of soft tissue and bone. Cancer 120: 1763-1774, 2014.

25. Go SI, Ko GH, Lee WS, Lee JH, Jeong SH, Lee YJ, Hong SC and Ha WS: The use of CD44 variant 9 and Ki-67 combination can predicts prognosis better than their single use in early gastric cancer. Cancer Res Treat 51: 1411-1419, 2019.

26. Yamamoto Y, Hayashi Y and Murakami I: Recurrence of solitary fibrous tumor/hemangiopericytoma could be predicted by Ki-67 regardless of its origin. Acta Med Okayama 74: 335-343, 2020.

27. Hayashi Y, Osanai M and Lee GH: Fascin-1 expression correlates with repression of E-cadherin expression in hepatocellular carcinoma cells and augments their invasiveness in combination with matrix metalloproteinases. Cancer Sci 102: 1228-1235, 2011.

28. Wang Q, Tang CH, Chuang HT, Li XN, Zhao YM, Su CM, Hu GN, Zhang F, Sun XX, Zen Y, et al: Fascin-1 as a novel diagnostic marker of triple-negative breast cancer. Cancer Med 5: 1983-1988, 2016.